What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection

Current Opinion in Infectious Diseases

Volumn 17, Issue 1, 2004, Pages 27-32

  Tien, Phyllis C ^a,b   Grunfeld, Carl ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Fat distribution; HIV; Lipoatrophy; Lipodystrophy; Lipohypertrophy

Indexed keywords

BODY FAT; EXAMINATION; HEALTH SURVEY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTERMETHOD COMPARISON; LIPOATROPHY; LIPOHYPERTROPHY; MEDICAL ASSESSMENT; MEDICAL LITERATURE; METHODOLOGY; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; REVIEW; SELF REPORT; CROSS-SECTIONAL STUDY; LIPODYSTROPHY; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PREVALENCE;

CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; LIPODYSTROPHY; LONGITUDINAL STUDIES; PREVALENCE;

EID: 3042821167     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200402000-00005     Document Type: Review

References (33)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-2505.
2. Lo JC, Mulligan K, Tai VW, et al. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351:867-870.
3. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 27:68-72.
4. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-875.
5. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12:F37-F39.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
7. Striker R, Conlin D, Marx M, Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998; 27:218-220.
8. Engelson ES, Kotler DP, Tan Y, et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999; 69:1162-1169.
9. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
10. Madge S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999; 13:735-737.
11. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13:465-471.
12. Dong KL, Bausserman LL, Flynn MM, et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr 1999; 21:107-113.
13. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14:37-49.
14. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
15. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-598.
16. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
17. Savés M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 34:1397-1405. This large cross-sectional study of HIV-infected men and women determines lipodystrophy in antiretroviral experienced patients and determines the effect of individual protease inhibitors and nucleoside reverse transcriptase inhibitors.
18. Galli M, Cozzi Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipolCoNa study. Arch Intern Med 2002; 162:2621-2628. This large prospective study determines the incidence of lipodystrophy in antiretroviral naïve HIV-infected men and women after initiation of antiretroviral therapy and determines the effect of individual protease inhibitors and nucleoside reverse transcriptase inhibitors, as well as protease inhibitor based highly active antiretroviral therapy regimens.
19. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr 2003; 34:58-61. This large cross-sectional study compared the prevalence of lipodystrophy between HIV-infected men and women. The percentage of women who had never been treated, had interrupted antiretroviral therapy, and were on suboptimal regimens with 2 nucleoside reverse transcriptase inhibitors was higher than in men.
20. Lichtenstein K, Delaney K, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56. This large prospective study determines the incidence and risk factors including host factors such as CD4 lymphocyte count, of peripheral lipoatrophy in HIV-infected patients.
21. Hadigan C, Miller K, Corcoran C, et al. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84:1932-1937.
22. Mercie P, Viallard JF, Thiebaut R, et al. Efavirenz-associated breast hypertrophy in HIV-infection patients. AIDS 2001; 15:126-129.
23. Heath K, Hogg R, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002; 30:440-447. This large prospective study determines the incidence of lipodystrophy in antiretroviral treated predominantly HIV-infected men and discusses their association with individual antiretroviral drugs.
24. Gripshover B, Tien P, Saag M, et al. Lipoatrophy is the dominant feature of the lipodystrophy syndrome in HIV-infected men. In: 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2003. Foundation for Retrovirology and Human Hearth, Alexandria, Virginia. p. 319. This large cross-sectional study determines the prevalence of lipoatrophy and lipohypertrophy both peripherally and centrally in HIV-infected men when compared with controls of similar age and concludes that lipoatrophy both peripherally and centrally predominates in HIV-infected men.
25. Tien P, Cole S, Williams C, et al. Incidence of lipoatrophy and lipohypertrophy in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2003; 34:461-466. This large prospective study compares the incidence of lipoatrophy and lipohypertrophy both peripherally and centrally in women with and at risk for HIV and concludes that lipoatrophy both peripherally and centrally predominates in HIV-infected women.
26. Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25:937-938.
27. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:228-237.
28. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361:726-735.
29. Saag M, Tien P, Gripshover B, et al. Body composition in HIV infected men with and without peripheral lipoatrophy is different than controls. In: 10th Conference on Retroviruses and Opportunistic Infections; Boston, MA; 2003. Foundation for Retrovirology and Human Health, Alexandria, Virginia. p. 320. This large cross-sectional study uses MRI to directly measure regional body fat and concludes that subcutaneous loss of fat predominates in HIV-infected men when compared with controls of similar age.
30. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquir Immune Defic Syndr 2002; 31:50-55. This large cross-sectional study determines the prevalence of lipodystrophy in antiretroviral treated HIV-infected patients and studies their association with stavudine, abacavir, and protease inhibitors.
31. Paech V, Lorenzen T, von Krosigk A, et al. Gynaecomastia in HIV-infected men: association with effects of antiretroviral therapy. AIDS 2002; 16:1193-1195. This is the largest cross-sectional study to date on gynaecomastia in HIV-infected men on antiretroviral therapy.
32. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS 2003; 17:971-979. This small prospective study of 40 antiretroviral naïve HIV-infected men followed for 96 weeks using body composition dual energy X-ray absorptiometry scans nicely outlines the body composition changes including gain in limb fat and abdominal fat in the first 24 weeks after starting therapy followed by persistent decreases in limb fat but maintenance of abdominal fat.
33. Levan P, Nguyen T, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS 2002; 16:1985-1987. This small study utilizes state-of-the-art MRI measurements of facial fat to follow patients after autologous facial fat transplant.